Dr Ken Lim has recently published a paper in Clinical Lymphoma, Myeloma & Leukaemia titled "Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients". This study used MRDR data to investigate the prognostic impact of 1q21+ (the gain/amplification of 1q21, a common secondary chromosomal abnormality) on patients treated with Dara-based regimens, as well as the influence of prognosis of increasing copies of 1q21.
Thank you to all patients, MRDR site staff and investigators for your contribution to this, and congratulations to Dr. Ken Lim on this publication!